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Abstract The planning of IVF treatment by scheduling menstruation and hence initiation of ovarian stimulation using sex-steroid
pre-treatment is commonly used. Pooling data from six randomized-controlled trials encompassing 1343 patients, with and without
combined oral contraceptive pill pre-treatment, suggests that the ongoing pregnancy rate per randomized woman is signiﬁcantly
lower in patients with oral contraceptive pill pre-treatment (relative risk [RR]: 0.80, 95% conﬁdence interval [CI]: 0.66–0.97; rate
difference [RD]: −5%, 95% CI: −10% to −1%; ﬁxed effects model). This ﬁnding remains remarkably robust in multiple sensitivity analy-
ses: exclusion of a study on poor responders, exclusion of the three smallest studies or exclusion of studies with a pill-free interval
of less than 5 days, results in RR of 0.78 (95% CI: 0.64–0.94), 0.80 (95% CI: 0.65–0.98) and 0.79, (95% CI: 0.64–0.99), respectively.
Furthermore, the ﬁnding of a signiﬁcant reduction in ongoing pregnancy rate is not inconsistent with other evidence from the lit-
erature. The potential beneﬁt of using oral contraceptive pill pre-treatment for cycle planning should therefore be balanced against
its detrimental effect. Further randomized studies should test whether an effect similar to the one observed after combined oral
contraceptive pill usage exists after other sex steroid pre-treatment regimens.
© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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We read with great interest the manuscript by
Garcia-Velasco and Fatemi (2015), recently published in
Reproductive Biomedicine Online, on the topic of oral con-
traceptive pill pre-treatment in ovarian stimulation utiliz-
ing gonadotrophin-releasing hormone (GnRH)-antagonists. As
a conclusion from a systematic literature review, and after
pooling data from six randomized-controlled trials encom-
passing 1343 patients, we previously reported that the ongoing
pregnancy rate per randomized woman is signiﬁcantly lower
in patients with oral contraceptive pill pre-treatment (rela-
tive risk [RR]: 0.80, 95% conﬁdence interval [CI]: 0.66–0.97;
rate difference [RD]: −5%, 95% CI: −10% to −1%; ﬁxed effects
model) (Griesinger et al., 2010).
Garcia-Velasco and Fatemi address several aspects of this
systematic review and scrutinize the internal validity as well
as the extent to which the conclusions of this study are ex-
ternally valid (‘clear consensus is lacking on whether pre-
treatment with combined oral contraceptives in ovarian
stimulation has a negative effect on pregnancy rates and live
birth’).
The following addresses the concerns of Garcia-Velasco and
Fatemi with the aim to provide a better understanding of
http://dx.doi.org/10.1016/j.rbmo.2015.04.001
1472-6483/© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
Reproductive BioMedicine Online (2015) 31, 6–8
www.sciencedirect .com
www.rbmonl ine.com
important aspects of the aforementioned systematic review
(Griesinger et al., 2010).
The ﬁrst point of criticism addresses the pooling of studies
conducted in normo-responder patientswith studies conducted
in poor-responder patients. Indeed, the meta-analysis in-
cluded one single study, performed in 54 poor responders, (Kim
et al., 2009) which has contributed to the pooled estimate of
a rate difference of −5% in ongoing pregnancy rates with oral
contraceptive pre-treatment. However, in order to account
for thepotential heterogeneity in outcomesbypopulation type,
a sensitivity analysis was included in the systematic review,
whichmight have slipped the attention of Garcia-Velasco and
Fatemi. The exclusion from the study of poor responder pa-
tients indeed increased the effect size to −6% rate difference
in ongoing pregnancy rate (RD: −6%, 95%, CI: −11% to −1%;
RR: 0.78, 95%, CI: 0.64 to 0.94) – not in favour of oral con-
traceptive pre-treatment (Griesinger et al., 2010).
Garcia-Velasco and Fatemi next question the pooling of
studies of different sample sizes in a meta-analysis. More spe-
ciﬁcally they express concern that randomized studies with
small sample sizes may carry ‘limitations and bias. . .when
looking at pregnancy rates’. Although it is agreed that studies
with small sample sizes suffer from imprecise effect size es-
timates, this is not necessarily a source of bias. Further-
more, a basic principle of meta-analysis dictates that during
the process of pooling aggregate data, individual studies are
weighted such that larger studies contribute more than smaller
studies to the estimated combined effect. The three smaller
studies (Cédrin-Durnerin et al., 2007; Huirne et al., 2006; Kim
et al., 2009) included in the systematic review contributed
only 11% weight to the conclusion, e.g. ongoing pregnancy rate
reduction with oral contraceptive pre-treatment (Figure 1 in
Griesinger et al., 2010). The exclusion of these three small
studies from the meta-analysis does not alter the conclu-
sion (RR: 0.80, 95% CI: 0.65–0.98). Furthermore, different
meta-analytical methods of synthesizing aggregate data in a
meta-analysis are available and one important difference
between these commonly used methods alludes to the way
that weight is attributed to individual study. From a sensi-
tivity analysis of the systematic review in question, regard-
ing ongoing pregnancy rate, it becomes clear that the effect
direction, the effect size and the precision with which the
effect size is estimated (e.g. 95% CI) are not altered by the
use of either a ﬁxed-effects model (Griesinger et al., 2010)
or random-effects model (Figure 1) for data synthesis.
Next, the potential impact of the clinical heterogeneity
between the pooled studies is addressed by Garcia-Velasco
and Fatemi. However, the studies included in the systematic
review are remarkably homogenous: 96% of patients are
normo-responders; all patients randomized to the study arm
of the studies received a combined oral contraceptive; in all
oral contraceptives the dose of ethinyl oestradiol was 30 µg;
and all studies used one of only two gestagens (either
desogestrel or levonorgestrel). Furthermore, all patients were
treated in a multiple dose GnRH-antagonist protocol and all
patients received recombinant FSH for ovarian stimulation.
As ‘most relevant’ in terms of clinical heterogeneity, Garcia-
Velasco and Fatemi identify the pooling of studies in which
the pill-free interval (the period between the cessation of the
oral contraceptive and the initiation of ovarian stimulation)
was either 2–3 days or 5 days. Although it is acknowledged
that this heterogeneity represents a potential limitation to
the external validity of the overall ﬁnding, we stress that
pooling of the three studies on normo-responder patients
(Cédrin-Durnerin et al., 2007; Kolibianakis et al., 2006;
Tavmergen et al., 2011) exclusively using (at least) a 5-day
pill-free interval also suggests that the probability of ongoing
pregnancy is signiﬁcantly decreased after oral contracep-
tive pre-treatement (RR: 0.79, 95% CI: 0.64–0.99, P = 0.04)
(Figure 2).
Eventually, Garcia-Velasco and Fatemi address what they
perceive as an inconsistency in the literature: While the sys-
tematic review in question comparing oral contraceptive pre-
treatment with no oral contraceptive pre-treatment in GnRH-
antagonist ovarian stimulation for IVF reports a signiﬁcant
reduction in ongoing pregnancy likelihood after oral contra-
ceptive pre-treatment, no such effect was found in a study
comparing long GnRH-agonist stimulation with no oral con-
traceptive pre-treatment with GnRH-antagonist stimulation
with oral contraceptive pre-treatment (Garcia Velasco et al.,
2011). However, not only is this approach comparing apples
with pears, but indeed the study ﬁnding of Garcia-Velasco
et al. (2011) is remarkably similar to the conclusion of our
systematic review in both the direction of the effect as well
as its magnitude. The ongoing pregnancy rate in their study
is reduced by −6% (95% CI: −18.8% to 6.7%) in patients after
oral contraceptive pre-treatment in a GnRH-antagonist pro-
tocol. In order however, to show that a difference of such mag-
nitude is not attributed to chance but rather represents a true
effect, a much larger sample size would be necessary. Thus
Figure 1 Pooled risk ratio and 95% CI for ongoing pregnancy rate per randomized woman in the six randomized control trials derived
from a random effects model. OCP = oral contraceptive pill; M-H = Mantel-Haenszel.
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the ﬁnding of ‘no difference’ in the study by Garcia-Velasco
et al. (2011) may well represent a type II error in statistical
hypothesis testing and this study result must therefore not
be interpreted as inconsistent with the existing literature.
In conclusion, the available data from randomized studies
suggest to this day that oral contraceptive pre-treatment in
GnRH-antagonist cycles for IVF is associated with a signiﬁ-
cantly reduced chance of ongoing pregnancy. This ﬁnding
remains remarkably robust in multiple different scenarios that
address the concerns of Garcia-Velasco and Fatemi (2015) en-
hancing our conﬁdence that it constitutes an accurate esti-
mate of the underlying effect. In light of this evidence,
randomized studies should be performed to prove or dis-
prove whether a similar effect exists after other oral con-
traceptive or stimulation protocols usage, and in other patient
populations.
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Figure 2 Risk ratio for ongoing pregnancy rate per randomized woman including only normo-responder studies with a pill-free interval
of at least 5 days. OCP = oral contraceptive pill; M-H = Mantel-Haenszel.
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